Catalent Inc., Somerset, NJ, has completed an Initial Public Offering and is now a publicly traded company on the New York Stock Exchange.  
 
The global provider of delivery technologies and development solutions for drugs, biologics and consumer health products, announced the pricing of its initial public offering of 42,500,000 shares of its common stock at $20.50 per share. The shares were expected to begin trading on the New York Stock Exchange on July 31, 2014 under the ticker symbol “CTLT,” with the offering closing on August 5, 2014, subject to customary closing conditions. Catalent has granted the underwriters a 30-day option to purchase up to an additional 6,375,000 at the initial public offering price.
 
Catalent expects to receive net proceeds of approximately $822.7 million after deducting underwriting discounts and estimated offering expenses, and intends to use the proceeds to reduce debt. Morgan Stanley, J.P. Morgan, BofA Merrill Lynch, Goldman, Sachs & Co., Jefferies and Deutsche Bank Securities are acting as joint bookrunning managers for the offering. Blackstone Capital Markets, Piper Jaffray, Raymond James, Wells Fargo Securities, William Blair and Evercore are acting as co-managers for the offering.
 
A registration statement relating to shares of the common stock of Catalent has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (SEC). The registration statement is available on the SEC’s website at www.sec.gov under the registrant’s name.